Nasdaq Cmpi News Today

Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) and IN8bio (NASDAQ:INAB – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends. Profitability This table compares Checkmate Pharmaceuticals and IN8bio’s net margins, […]

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 78,900 shares, a growth of 71.5% from the April 30th total of 46,000 shares. Currently, 1.2% of the company’s stock are sold short. Based […]

Small-cap stocks are companies with market capitalizations of less than $2 billion. These stocks can be very volatile, and thus, could offer impressiv

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) major shareholder Global Strategic Fund I. Venbio sold 17,600 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $10.37, for a total transaction of $182,512.00. Following the completion of the transaction, the insider now […]

Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports. According to Zacks, “Checkmate Pharmaceuticals Inc. is a clinical stage biotechnology company. It is focused on developing proprietary technology to harness the power of the immune […]

Brokerages expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) to report earnings of ($0.73) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Checkmate Pharmaceuticals’ earnings. Checkmate Pharmaceuticals reported earnings per share of ($0.65) during the same quarter last year, which indicates a negative year-over-year growth rate of […]

Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) announced its quarterly earnings results on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.12, Fidelity Earnings reports. NASDAQ:CMPI traded up $0.01 on Thursday, hitting $3.22. The stock had a trading volume of 10,192 shares, compared to its […]

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical...